Fig. 3From: Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging studyFasting plasma glucose change from baseline to Week 12—adjusted mean and 90% CI (ITT population). EVO evogliptin, FPG fasting plasma glucose, SITA sitagliptinBack to article page